232 related articles for article (PubMed ID: 32845723)
1. CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders.
Jallaq SA; Verba M; Strawn JR; Martin LJ; DelBello MP; Ramsey LB
J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):56-62. PubMed ID: 32845723
[No Abstract] [Full Text] [Related]
2. Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents.
Kanu AA; Johnston MM; Poweleit EA; Vaughn SE; Strawn JR; Ramsey LB
J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):34-41. PubMed ID: 38377522
[No Abstract] [Full Text] [Related]
3. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.
Tveito M; Molden E; Høiseth G; Correll CU; Smith RL
Eur J Clin Pharmacol; 2020 Jan; 76(1):41-49. PubMed ID: 31637453
[TBL] [Abstract][Full Text] [Related]
4. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis.
Zhang X; Xiang Q; Zhao X; Ma L; Cui Y
J Clin Pharm Ther; 2019 Apr; 44(2):163-173. PubMed ID: 30565279
[TBL] [Abstract][Full Text] [Related]
5. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
6. Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.
Liao Y; Sun Y; Guo J; Kang Z; Sun Y; Zhang Y; He J; Huang C; Sun X; Zhang JM; Wang J; Wang HN; Chen ZY; Wang K; Pan J; Ni AH; Weng S; Wang A; Cao C; Sun L; Zhang Y; Kuang L; Zhang Y; Liu Z; Yue W;
EBioMedicine; 2024 Jun; 104():105165. PubMed ID: 38776596
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
[TBL] [Abstract][Full Text] [Related]
10. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
Hendset M; Hermann M; Lunde H; Refsum H; Molden E
Eur J Clin Pharmacol; 2007 Dec; 63(12):1147-51. PubMed ID: 17828532
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines.
Gerlach S; Maruf AA; Shaheen SM; McCloud R; Heintz M; McAusland L; Arnold PD; Bousman CA
Pharmacogenet Genomics; 2024 Jul; 34(5):149-153. PubMed ID: 38517706
[TBL] [Abstract][Full Text] [Related]
12. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.
de Leon J; Susce MT; Pan RM; Fairchild M; Koch WH; Wedlund PJ
J Clin Psychiatry; 2005 Jan; 66(1):15-27. PubMed ID: 15669884
[TBL] [Abstract][Full Text] [Related]
13. Pediatric CYP2D6 metabolizer status and post-tonsillectomy nausea and vomiting after ondansetron.
Black K; Brenn BR; Gaedigk A; Wanderer JP; Van Driest SL
Clin Transl Sci; 2023 Feb; 16(2):269-278. PubMed ID: 36350309
[TBL] [Abstract][Full Text] [Related]
14. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2D6 genotype on duloxetine serum concentration.
Hole K; Gangsø S; Jensstuen ÅT; Ormøy HH; Paulsen M; Molden E; Haslemo T
Basic Clin Pharmacol Toxicol; 2024 Jan; 134(1):186-192. PubMed ID: 37864290
[TBL] [Abstract][Full Text] [Related]
17. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
[TBL] [Abstract][Full Text] [Related]
18. Frequencies of
Scherf-Clavel M; Weber H; Unterecker S; Müller DJ; Deckert J
World J Biol Psychiatry; 2024 Apr; 25(4):214-221. PubMed ID: 38493365
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.
Kneller LA; Zubiaur P; Koller D; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2021 Dec; 60(12):1569-1582. PubMed ID: 34125422
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.
Scherf-Clavel M; Frantz A; Eckert A; Weber H; Unterecker S; Deckert J; Reif A; Hahn M
Int J Clin Pharm; 2023 Oct; 45(5):1107-1117. PubMed ID: 37166747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
